{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Anemia, Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Fatigue, Grade2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Infusion related reaction. Grade2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Alanine aminotransferase increased, Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Alkaline phosphatase increased, Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Anorexia, Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Blood bilirubin increased, Grade1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Diarrhea, Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Diabetic ketoacidosis, Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Back pain, Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Diverticulitis per upper GI series, Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hypokalemia, Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hyponatremia, Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Nausea, Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Rash maculo-papular, Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Urticaria, Grade 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"To describe the safety profile of avelumab monotherapy in patients with advanced or metastatic small intestinal adenocarcinoma","groups":[{"description":"Participants receive avelumab by IV infusion following pretreatment with H1 blockers and acetaminophen once every 2 weeks.\n\nAvelumab: Avelumab through a vein once every 2 weeks","id":"OG000","title":"Avelumab Monotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"all participants","reportingStatus":"POSTED","timeFrame":"On-study date to 30 days following final dose of study drug, or until the event is resolved, stabilized, or determined to be irreversible by the participating investigator if beyond 30 days.","title":"Number of Patients With Each Worst-Grade Toxicity","type":"PRIMARY","unitOfMeasure":"Participants"}